Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 15/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 9/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30433252 | 1.00 | SSTR4 (0.42) | SSTR4KDRFGFR3KDM4EALDH1A1 | |
| SCHEMBL30432339 | 0.87 | SSTR4 (0.42) | SSTR4KDRFGFR3KDM4EALDH1A1 | |
| SCHEMBL25168867 | 0.87 | SSTR4 (0.42) | SSTR4KDRFGFR3KDM4EALDH1A1 | |
| SCHEMBL23726936 | 0.86 | KDR (0.40) | KDRFGFR3KDM4EALDH1A1GAA | |
| SCHEMBL25664063 | 0.86 | SSTR4 (0.38) | SSTR4KDRFGFR3KDM4EALDH1A1 | |
| SCHEMBL25664062 | 0.85 | SSTR4 (0.37) | SSTR4KDRFGFR3KDM4EALDH1A1 | |
| SCHEMBL23725835 | 0.85 | KDR (0.36) | SSTR4KDRFGFR3KDM4EALDH1A1 | |
| SCHEMBL30432756 | 0.84 | SSTR4 (0.40) | SSTR4KDRFGFR3KDM4EALDH1A1 | |
| SCHEMBL25664078 | 0.84 | SSTR4 (0.40) | SSTR4KDRFGFR3KDM4EALDH1A1 | |
| SCHEMBL30432664 | 0.79 | SSTR4 (0.33) | SSTR4KDRFGFR3KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | HAVCR2, HMBS, VHL | SSTR4 3227/4885KDR 3652/4885FGFR3 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.